Jacobs Bruce N.

Chief Financial OfficerKymera Therapeutics, Inc. (KYMR) · full profile →Form 4 · filed Jul 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8.9M
Net Open-Market Flow
-$8.9M
Transactions
10
9 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)61K$5.33$327K322K
Jun 30, 2026Sell(S)2K$110.54$166K320K
Jun 30, 2026Sell(S)2K$111.57$190K319K
Jun 30, 2026Sell(S)1K$112.79$124K318K
Jun 30, 2026Sell(S)4K$114.19$469K314K
Jun 30, 2026Sell(S)51K$114.77$5.9M262K
Jun 30, 2026Sell(S)8K$115.82$923K254K
Jun 30, 2026Sell(S)6K$116.99$720K248K
Jun 30, 2026Sell(S)3K$117.70$377K245K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)61K$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-295090) within minutes of acceptance. Every field above traces to the original document. Verify it directly: